Canafax D M, Torres A, Fryd D S, Heil J E, Strand M H, Ascher N L, Payne W D, Sutherland D E, Simmons R L, Najarian J S
Transplantation. 1986 Feb;41(2):177-81. doi: 10.1097/00007890-198602000-00009.
We randomized 158 recipients of cadaver renal allografts to cyclosporine-prednisone (83) or antilymphocyte globulin-azathioprine-prednisone (75) to evaluate: the effects of immunosuppression and pretransplant risk factors on the incidence of delayed graft function, the effects of immunosuppression on the resolution of delayed graft function, and the effects of delayed graft function and pretransplanted risk factors on patient and graft survival. Cyclosporine did not increase the incidence of delayed graft function, compared with ALG-azathioprine-treated patients (33% versus 27%, P = 0.550) but doubled the mean (+/- SD) duration of oliguria (11.8 +/- 11.0 versus 5.9 +/- 3.2 days, P = 0.002) and the number of required dialyses (6.6 +/- 7.6 versus 3.2 +/- 1.3, P = 0.031). Retransplanted patients had a higher incidence of delayed graft function that recipients of primary grafts in both the cyclosporine (82% versus 25%, P = 0.001) and ALG-azathioprine (55% versus 22%, P = 0.025) treatment groups. The presence of delayed function reduced one-year graft survival from 89% in all patients without delayed function to 72% (P = 0.011) in all patients with delayed function. Cyclosporine-treated patients had a slightly, but not significantly better one-year graft survival rate than ALG-azathioprine treated patients both with (73% versus 68%, P = 0.750) and without (92% versus 82%, P = 0.069) delayed graft function. A preservation time longer than 24 hr did not increase the incidence of delayed graft function in cyclosporine-treated patients (34% versus 32%, P = 0.811) or ALG-azathioprine-treated patients (27% versus 27%, P = 0.902). Cyclosporine-treated patients given kidneys with greater than 24 hr of preservation time had reduced graft survival only when delayed graft function occurred (67% versus 92%, P = 0.009). In conclusion, (1) cyclosporine did not increase the incidence of delayed graft function over ALG-azathioprine treatment; (2) cyclosporine did significantly slow recovery of kidneys with delayed function; (3) delayed graft function correlated with poorer graft survival rate in both treatment groups; but (4) prolonged preservation time did not increase the incidence of delayed graft function or reduce graft survival.
我们将158例尸体肾移植受者随机分为环孢素 - 泼尼松组(83例)和抗淋巴细胞球蛋白 - 硫唑嘌呤 - 泼尼松组(75例),以评估:免疫抑制和移植前危险因素对移植肾功能延迟发生率的影响、免疫抑制对移植肾功能延迟恢复的影响,以及移植肾功能延迟和移植前危险因素对患者及移植肾存活的影响。与接受抗淋巴细胞球蛋白 - 硫唑嘌呤治疗的患者相比,环孢素并未增加移植肾功能延迟的发生率(33%对27%,P = 0.550),但使少尿的平均(±标准差)持续时间增加了一倍(11.8±11.0天对5.9±3.2天,P = 0.002),以及所需透析次数增加(6.6±7.6次对3.2±1.3次,P = 0.031)。在环孢素治疗组(82%对25%,P = 0.001)和抗淋巴细胞球蛋白 - 硫唑嘌呤治疗组(55%对22%,P = 0.025)中,再次移植的患者移植肾功能延迟的发生率均高于初次移植的受者。移植肾功能延迟的存在使所有患者的一年移植肾存活率从无移植肾功能延迟患者的89%降至有移植肾功能延迟患者的72%(P = 0.011)。环孢素治疗的患者,无论有无移植肾功能延迟,其一年移植肾存活率均略高于抗淋巴细胞球蛋白 - 硫唑嘌呤治疗的患者,但差异无统计学意义(有移植肾功能延迟时为73%对68%,P = 0.750;无移植肾功能延迟时为92%对82%,P = 0.069)。保存时间超过24小时,在环孢素治疗的患者(34%对32%,P = 0.811)或抗淋巴细胞球蛋白 - 硫唑嘌呤治疗的患者(27%对27%,P = 0.902)中,均未增加移植肾功能延迟的发生率。保存时间超过24小时的肾脏给予环孢素治疗的患者,仅在发生移植肾功能延迟时移植肾存活率降低(67%对92%,P = 0.009)。总之,(1)与抗淋巴细胞球蛋白 - 硫唑嘌呤治疗相比,环孢素未增加移植肾功能延迟的发生率;(2)环孢素确实显著延缓了移植肾功能延迟的肾脏恢复;(3)在两个治疗组中,移植肾功能延迟均与较差的移植肾存活率相关;但(4)延长保存时间未增加移植肾功能延迟的发生率,也未降低移植肾存活率。